Zoe R Simmons1, Savita Sharma1, Jeremiah Wayne1, Sheng Li2, Craig W Vander Kooi3, Matthew S Gentry4. 1. Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY 40536, United States. 2. Department of Medicine, University of California at San Diego, La Jolla, CA 92093, United States. 3. Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY 40536, United States; Lafora Epilepsy Cure Initiative, University of Kentucky College of Medicine, Lexington, KY 40536, United States. 4. Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY 40536, United States; Lafora Epilepsy Cure Initiative, University of Kentucky College of Medicine, Lexington, KY 40536, United States. Electronic address: matthew.gentry@uky.edu.
Abstract
OBJECTIVES: Mutations in the gene encoding the glycogen phosphatase laforin result in the fatal childhood dementia Lafora disease (LD). A cellular hallmark of LD is cytoplasmic, hyper-phosphorylated, glycogen-like aggregates called Lafora bodies (LBs) that form in nearly all tissues and drive disease progression. Additional tools are needed to define the cellular function of laforin, understand the pathological role of laforin in LD, and determine the role of glycogen phosphate in glycogen metabolism. In this work, we present the generation and characterization of laforin nanobodies, with one being a laforin inhibitor. DESIGN AND METHODS: We identify multiple classes of specific laforin-binding nanobodies and determine their binding epitopes using hydrogen deuterium exchange (HDX) mass spectrometry. Using para-nitrophenyl phosphate (pNPP) and a malachite gold-based assay specific for glucan phosphatase activity, we assess the inhibitory effect of one nanobody on laforin's catalytic activity. RESULTS: Six families of laforin nanobodies are characterized and their epitopes mapped. One nanobody is identified and characterized that serves as an inhibitor of laforin's phosphatase activity. CONCLUSIONS: The six generated and characterized laforin nanobodies, with one being a laforin inhibitor, are an important set of tools that open new avenues to define unresolved glycogen metabolism questions.
OBJECTIVES: Mutations in the gene encoding the glycogen phosphatase laforin result in the fatal childhood dementia Lafora disease (LD). A cellular hallmark of LD is cytoplasmic, hyper-phosphorylated, glycogen-like aggregates called Lafora bodies (LBs) that form in nearly all tissues and drive disease progression. Additional tools are needed to define the cellular function of laforin, understand the pathological role of laforin in LD, and determine the role of glycogen phosphate in glycogen metabolism. In this work, we present the generation and characterization of laforin nanobodies, with one being a laforin inhibitor. DESIGN AND METHODS: We identify multiple classes of specific laforin-binding nanobodies and determine their binding epitopes using hydrogen deuterium exchange (HDX) mass spectrometry. Using para-nitrophenyl phosphate (pNPP) and a malachite gold-based assay specific for glucan phosphatase activity, we assess the inhibitory effect of one nanobody on laforin's catalytic activity. RESULTS: Six families of laforin nanobodies are characterized and their epitopes mapped. One nanobody is identified and characterized that serves as an inhibitor of laforin's phosphatase activity. CONCLUSIONS: The six generated and characterized laforin nanobodies, with one being a laforin inhibitor, are an important set of tools that open new avenues to define unresolved glycogen metabolism questions.
Authors: B A Minassian; L Ianzano; M Meloche; E Andermann; G A Rouleau; A V Delgado-Escueta; S W Scherer Journal: Neurology Date: 2000-08-08 Impact factor: 9.910
Authors: Vincent S Tagliabracci; Christian Heiss; Chandra Karthik; Christopher J Contreras; John Glushka; Mayumi Ishihara; Parastoo Azadi; Thomas D Hurley; Anna A DePaoli-Roach; Peter J Roach Journal: Cell Metab Date: 2011-03-02 Impact factor: 27.287
Authors: Buyun Tang; Mykhaylo S Frasinyuk; Vimbai M Chikwana; Krishna K Mahalingan; Cynthia A Morgan; Dyann M Segvich; Svitlana P Bondarenko; Galyna P Mrug; Przemyslaw Wyrebek; David S Watt; Anna A DePaoli-Roach; Peter J Roach; Thomas D Hurley Journal: J Med Chem Date: 2020-03-23 Impact factor: 7.446
Authors: Ross W Cheloha; Thibault J Harmand; Charlotte Wijne; Thomas U Schwartz; Hidde L Ploegh Journal: J Biol Chem Date: 2020-08-31 Impact factor: 5.157
Authors: Matthew S Gentry; Joan J Guinovart; Berge A Minassian; Peter J Roach; Jose M Serratosa Journal: J Biol Chem Date: 2018-02-26 Impact factor: 5.157
Authors: Bartholomew A Pederson; Julie Turnbull; Jonathan R Epp; Staci A Weaver; Xiaochu Zhao; Nela Pencea; Peter J Roach; Paul W Frankland; Cameron A Ackerley; Berge A Minassian Journal: Ann Neurol Date: 2013-08 Impact factor: 10.422
Authors: Felix Nitschke; Mitchell A Sullivan; Peixiang Wang; Xiaochu Zhao; Erin E Chown; Ami M Perri; Lori Israelian; Lucia Juana-López; Paola Bovolenta; Santiago Rodríguez de Córdoba; Martin Steup; Berge A Minassian Journal: EMBO Mol Med Date: 2017-07 Impact factor: 12.137
Authors: Dominik Schumacher; Jonas Helma; Anselm F L Schneider; Heinrich Leonhardt; Christian P R Hackenberger Journal: Angew Chem Int Ed Engl Date: 2018-01-26 Impact factor: 15.336
Authors: Jonathan R Hart; Xiao Liu; Chen Pan; Anyi Liang; Lynn Ueno; Yingna Xu; Alexandra Quezada; Xinyu Zou; Su Yang; Qingtong Zhou; Steve Schoonooghe; Gholamreza Hassanzadeh-Ghassabeh; Tian Xia; Wenqing Shui; Dehua Yang; Peter K Vogt; Ming-Wei Wang Journal: Proc Natl Acad Sci U S A Date: 2022-09-12 Impact factor: 12.779